Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Siegel

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Plos One|July 1, 2020
Are chief executive officers more likely to be first-borns?Cláudia Custódio, Stephan Siegel
Epigenomics|June 17, 2015
Targeting BET bromodomains for cancer treatmentMarie Jung, Kathy A Gelato, Amaury Fernández-Montalván, et al.
Angewandte Chemie (International Ed. in English)|May 2, 2018
Memory of Chirality in Electron Transfer Mediated Benzylic Umpolung Reactions of Arene-Cr(CO)<sub>3</sub> ComplexesHans-Günther Schmalz, Charles B de Koning, Dirk Bernicke, et al.
Journal of Medicinal Chemistry|September 28, 2022
Linker-Dependent Folding Rationalizes PROTAC Cell PermeabilityVasanthanathan Poongavanam, Yoseph Atilaw, Stephan Siegel, et al.
Bioorganic & Medicinal Chemistry Letters|August 9, 2005
Novel, selective indole-based ECE inhibitors: lead optimization via solid-phase and classical synthesisMichael Brands, Jens-Kerim Ergüden, Kentaro Hashimoto, et al.
Chemmedchem|August 8, 2006
Selective indole-based ECE inhibitors: synthesis and pharmacological evaluationMichael Brands, Jens-Kerim Ergüden, Kentaro Hashimoto, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2004
New class of bacterial phenylalanyl-tRNA synthetase inhibitors with high potency and broad-spectrum activityDieter Beyer, Hein-Peter Kroll, Rainer Endermann, et al.
Oncotarget|May 4, 2018
BET inhibition is an effective approach against KRAS-driven PDAC and NSCLCToni Jauset, Daniel Massó-Vallés, Sandra Martínez-Martín, et al.
Cancers|January 18, 2020
Characterization of the Menin-MLL Interaction as Therapeutic Cancer TargetKrzysztof Brzezinka, Ekaterina Nevedomskaya, Ralf Lesche, et al.
British Journal of Haematology|June 28, 2017
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphomaElena Bernasconi, Eugenio Gaudio, Pascale Lejeune, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Plos One|July 1, 2020
Are chief executive officers more likely to be first-borns?Cláudia Custódio, Stephan Siegel
Epigenomics|June 17, 2015
Targeting BET bromodomains for cancer treatmentMarie Jung, Kathy A Gelato, Amaury Fernández-Montalván, et al.
Angewandte Chemie (International Ed. in English)|May 2, 2018
Memory of Chirality in Electron Transfer Mediated Benzylic Umpolung Reactions of Arene-Cr(CO)<sub>3</sub> ComplexesHans-Günther Schmalz, Charles B de Koning, Dirk Bernicke, et al.
Journal of Medicinal Chemistry|September 28, 2022
Linker-Dependent Folding Rationalizes PROTAC Cell PermeabilityVasanthanathan Poongavanam, Yoseph Atilaw, Stephan Siegel, et al.
Bioorganic & Medicinal Chemistry Letters|August 9, 2005
Novel, selective indole-based ECE inhibitors: lead optimization via solid-phase and classical synthesisMichael Brands, Jens-Kerim Ergüden, Kentaro Hashimoto, et al.
Chemmedchem|August 8, 2006
Selective indole-based ECE inhibitors: synthesis and pharmacological evaluationMichael Brands, Jens-Kerim Ergüden, Kentaro Hashimoto, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2004
New class of bacterial phenylalanyl-tRNA synthetase inhibitors with high potency and broad-spectrum activityDieter Beyer, Hein-Peter Kroll, Rainer Endermann, et al.
Oncotarget|May 4, 2018
BET inhibition is an effective approach against KRAS-driven PDAC and NSCLCToni Jauset, Daniel Massó-Vallés, Sandra Martínez-Martín, et al.
Cancers|January 18, 2020
Characterization of the Menin-MLL Interaction as Therapeutic Cancer TargetKrzysztof Brzezinka, Ekaterina Nevedomskaya, Ralf Lesche, et al.
British Journal of Haematology|June 28, 2017
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphomaElena Bernasconi, Eugenio Gaudio, Pascale Lejeune, et al.
Pageof 2